12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Enzalutamide regulatory update

Medivation submitted an NDA to FDA for enzalutamide to treat castration-resistant prostate cancer (CRPC) in patients previously treated with docetaxel. The company requested...

Read the full 93 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >